Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts
Intrastriatal transplantation of dopaminergic neurones aims to repair the selective loss of nigrostriatal projections and the consequent dysfunction of striatocortical circuitries in Parkinson's disease (PD). Here, we have studied the effects of bilateral human embryonic dopaminergic grafts on...
Saved in:
Published in: | Annals of neurology Vol. 48; no. 5; pp. 689 - 695 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
John Wiley & Sons, Inc
01-11-2000
Willey-Liss |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Intrastriatal transplantation of dopaminergic neurones aims to repair the selective loss of nigrostriatal projections and the consequent dysfunction of striatocortical circuitries in Parkinson's disease (PD). Here, we have studied the effects of bilateral human embryonic dopaminergic grafts on the movement‐related activation of frontal cortical areas in 4 PD patients using H215O positron emission tomography and a joystick movement task. At 6.5 months after transplantation, mean striatal dopamine storage capacity as measured by 18F‐dopa positron emission tomography was already significantly elevated in these patients. This was associated with a modest clinical improvement on the Unified Parkinson's Disease Rating Scale, whereas the impaired cortical activation was unchanged. At 18 months after surgery, there was further significant clinical improvement in the absence of any additional increase in striatal 18F‐dopa uptake. Rostral supplementary motor and dorsal prefrontal cortical activation during performance of joystick movements had significantly improved, however. Our data suggest that the function of the graft goes beyond that of a simple dopamine delivery system and that functional integration of the grafted neurones within the host brain is necessary to produce substantial clinical recovery in PD. Ann Neurol 2000;48:689–695 |
---|---|
Bibliography: | European Union (Biomed 2 - No. BMH4-CT95-0341 ArticleID:ANA1 United Kingdom Parkinson's Disease Society Gemeinnützige Hertie Stiftung ark:/67375/WNG-M89L7PNV-3 Kock, Wiberg, Söderberg, and King Gustav V and Queen Victoria Foundations istex:1AF922B84B12ADC7614A1E55EE8602B8A2D4EE58 British and Swedish Medical Research Council ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0364-5134 1531-8249 1531-8249 |
DOI: | 10.1002/1531-8249(200011)48:5<689::AID-ANA1>3.0.CO;2-N |